Zeaxanthin prevents ferroptosis by promoting mitochondrial function and inhibiting the p53 pathway in free fatty acid-induced HepG2 cells.
暂无分享,去创建一个
Jingsheng Liu | Meihong Liu | Huimin Liu | Zhibo Jin | C. Wang | Jie Yan | Jiahan Xie | Fengtao Guan
[1] A. O’Halloran,et al. Plasma lutein and zeaxanthin concentrations associated with musculoskeletal health and incident frailty in The Irish Longitudinal Study on Ageing (TILDA) , 2022, Experimental Gerontology.
[2] W. Gu,et al. p53 in ferroptosis regulation: the new weapon for the old guardian , 2022, Cell Death & Differentiation.
[3] Z. Zuo,et al. Mitochondria damage and ferroptosis involved in Ni-induced hepatotoxicity in mice. , 2021, Toxicology.
[4] Mingzhu Zheng,et al. Zeaxanthin ameliorates obesity by activating the β3-adrenergic receptor to stimulate inguinal fat thermogenesis and modulating the gut microbiota. , 2021, Food & function.
[5] Xia Li,et al. p53: A Double-Edged Sword in Tumor Ferroptosis. , 2021, Pharmacological research.
[6] R. Weiskirchen,et al. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. , 2021, Clinica chimica acta; international journal of clinical chemistry.
[7] Yulong Chen,et al. Ferroptosis as a new therapeutic opportunity for nonviral liver disease. , 2021, European journal of pharmacology.
[8] Zifeng Huang,et al. Niujiaodihuang Detoxify Decoction inhibits ferroptosis by enhancing glutathione synthesis in acute liver failure models. , 2021, Journal of ethnopharmacology.
[9] R. Liu,et al. Goji berry (Lycium spp.) extracts exhibit antiproliferative activity via modulating cell cycle arrest, cell apoptosis, and the p53 signaling pathway. , 2021, Food & function.
[10] C. Hölscher,et al. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis , 2021, Journal of Natural Medicines.
[11] A. Belaidi,et al. Ferroptosis: mechanisms and links with diseases , 2021, Signal Transduction and Targeted Therapy.
[12] L. Zhuang,et al. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy , 2020, Protein & Cell.
[13] X. Shan,et al. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. , 2020, Toxicology.
[14] N. Sata,et al. Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetaminophen-induced acute liver failure , 2020, Cell Death & Disease.
[15] Can Liu,et al. Mitochondria regulation in ferroptosis. , 2019, European journal of cell biology.
[16] T. Efferth,et al. Pinolenic acid ameliorates oleic acid-induced lipogenesis and oxidative stress via AMPK/SIRT1 signaling pathway in HepG2 cells. , 2019, European journal of pharmacology.
[17] Xinting Sun,et al. Theaflavic acid from black tea protects PC12 cells against ROS-mediated mitochondrial apoptosis induced by OGD/R via activating Nrf2/ARE signaling pathway , 2019, Journal of Natural Medicines.
[18] T. Vanden Berghe,et al. Targeting Ferroptosis to Iron Out Cancer. , 2019, Cancer cell.
[19] H. Nakano,et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis , 2019, Cell Death & Disease.
[20] K. Christensen,et al. Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among US Adults, NHANES 2003–2014 , 2019, Nutrients.
[21] Mingzhu Zheng,et al. Zeaxanthin promotes mitochondrial biogenesis and adipocyte browning via AMPKα1 activation. , 2019, Food & function.
[22] Minghui Gao,et al. Role of Mitochondria in Ferroptosis. , 2019, Molecular cell.
[23] Bumseok Kim,et al. Ferroptosis affects the progression of non-alcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. , 2019, The American journal of pathology.
[24] Miao Sui,et al. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[25] Li Ma,et al. Total sesquiterpene glycosides from Loquat (Eriobotrya japonica) leaf alleviate high-fat diet induced non-alcoholic fatty liver disease through cytochrome P450 2E1 inhibition. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[26] F. Akhlaghi,et al. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters , 2017, Drug metabolism reviews.
[27] G. Liew,et al. Lutein and Zeaxanthin—Food Sources, Bioavailability and Dietary Variety in Age-Related Macular Degeneration Protection , 2017, Nutrients.
[28] W. Gu,et al. Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression. , 2016, Cell reports.
[29] W. Gu,et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses , 2016, Proceedings of the National Academy of Sciences.
[30] E. Tsochatzis,et al. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). , 2016, Metabolism: clinical and experimental.
[31] S. Dixon,et al. Mechanisms of ferroptosis , 2016, Cellular and Molecular Life Sciences.
[32] W. Gu,et al. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses , 2015, Cell cycle.
[33] Li-ping Hao,et al. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats. , 2015, World journal of gastroenterology.
[34] W. Gu,et al. Ferroptosis as a p53-mediated activity during tumour suppression , 2015, Nature.
[35] C. Byrne,et al. NAFLD: a multisystem disease. , 2015, Journal of hepatology.
[36] F. Nassir,et al. Role of Mitochondria in Nonalcoholic Fatty Liver Disease , 2014, International journal of molecular sciences.
[37] Matthew E. Welsch,et al. Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.
[38] R. Xavier,et al. Autosis is a Na+,K+-ATPase–regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia–ischemia , 2013, Proceedings of the National Academy of Sciences.
[39] P. Barberger‐Gateau,et al. Association of macular pigment density with plasma ω-3 fatty acids: the PIMAVOSA study. , 2012, Investigative ophthalmology & visual science.
[40] L. N. Valenti,et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. , 2011, QJM : monthly journal of the Association of Physicians.
[41] H. Tilg,et al. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.
[42] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[43] F. Murray-Zmijewski,et al. A complex barcode underlies the heterogeneous response of p53 to stress , 2008, Nature Reviews Molecular Cell Biology.
[44] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[45] Susan E Hankinson,et al. The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. Overview. , 2002, The Journal of nutrition.
[46] M. Tso,et al. Absorption and tissue distribution of zeaxanthin and lutein in rhesus monkeys after taking Fructus lycii (Gou Qi Zi) extract. , 2001, Investigative ophthalmology & visual science.
[47] D. Snodderly,et al. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. , 2000, The American journal of clinical nutrition.